Cover Picture: Liquid biopsy is emerging as a revolutionary new tool in cancer diagnostics and treatment monitoring. Like a mirror lake - reflecting the sun, sky and mountains - circulating tumor DNA (ctDNA) reflects typical features of medulloblastoma, the most common malignant brain tumor in children. The changes in biomarker level after treatment (surgery, radio- and chemotherapy) resemble the skyline of mountains and can be monitored by repeated analysis of blood or cerebrospinal fluid (CSF). Eibl and Schneemann originally developed brain tumor models, which finally allowed Eibl to confirm his medulloblastoma-like model by detecting the first p53 mutations in human medulloblastoma. 25 years later, such mutations were included as a critical part in the new World Health Organization (WHO) molecular classification of medulloblastoma, the current gold-standard in diagnostics. Here, Eibl and Schneemann summarize the recent developments and application of this knowledge in liquid biopsy and the challenges for improving the clinical management of patients with medulloblastoma.
view this paper